DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo

EVONILE vs FABTECH: Stock Comparison

EVONILE PHARMA vs FABTECH TECHNOLOGIESUpdated 6 Nov 26, 4:08 PM ISTNSE & company filings

EVONILE PHARMA is the larger company by market capitalisation. EVONILE PHARMA shows a lower P/E, while FABTECH TECHNOLOGIES shows a higher dividend yield, faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

EVONILE leads 2; FABTECH leads 4 of 6

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

EVONILEFABTECH

Valuation lens

What price are you paying?

Market CapContext only
₹4,233 Cr
₹595 Cr
P/E RatioEVONILE has the lower reading
0x ✓
11.89x
P/B RatioEVONILE has the lower reading
0x ✓
1.38x
EPSSame reading
—
₹3.38
Book ValueContext only
—
₹94.43
Dividend YieldFABTECH has the higher reading
0%
0.45% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
EVONILE is the larger company
₹4,233 Cr vs ₹595 Cr
P/E Ratio
EVONILE has a lower P/E
0x vs 11.89x
P/B Ratio
EVONILE has a lower P/B
0x vs 1.38x
Dividend Yield
FABTECH has a higher dividend yield
0.45% vs 0%
Revenue Growth (TTM YoY)
FABTECH has faster revenue growth
17.5% vs 0%
EPS Growth (TTM YoY)
FABTECH has faster EPS growth
23.4% vs 0%
Net Margin
FABTECH has a higher net margin
11.28% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricEVONILEFABTECH
Sector—Healthcare
Industry—Medical Equipment & Supplies

Price

MetricEVONILEFABTECH
Live Price₹1,758.4₹131.98
Day Change2.44%-1.78%
Volume52,65437,263
52-Week High₹1,738₹258
52-Week Low₹1,600.1₹115.1
Distance from 52W High1.17%-48.84%

Valuation

MetricEVONILEFABTECH
Market Cap₹4,233 Cr₹595 Cr
P/E Ratio0x11.89x
P/B Ratio0x1.38x
EPS—₹3.38
Book Value—₹94.43
Dividend Yield0%0.45%

Growth

MetricEVONILEFABTECH
Revenue Growth (TTM YoY)0%17.5%
EPS Growth (TTM YoY)0%23.4%
Qtr Sales Growth—22.81%
Qtr Profit Growth—256.86%

Profitability & Leverage

MetricEVONILEFABTECH
ROE—9.14%
ROCE—10.98%
Net Margin0%11.28%
Operating Margin—12.67%
Debt to Equity—0.1x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricEVONILEFABTECH
Promoter Holding—69.03%▲ 0.09 pp
FII Holding—0.02%
DII Holding—2.45%
Public Holding—28.49%▼ 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: EVONILE PHARMA and FABTECH TECHNOLOGIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.